Long-term outcomes for off-pump and on-pump CABG are similar
1. Composite outcome of death, stroke, MI, renal failure, or repeat coronary revascularization at 5 years was not significantly different...
![Galangin may sensitize apoptosis-resistant renal carcinoma cells [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2016/01/Papillary_renal_cell_carcinoma_-_very_high_mag-350x250.jpg)
Sunitinib increases disease free survival in high risk renal carcinoma post nephrectomy
1. In patients with locoregional clear-cell renal cell carcinoma (RCC) at high risk of recurrence post nephrectomy, those taking sunitinib...
Everolimus-eluting stents noninferior to CABG for left main coronary disease: The EXCEL trial
1. Rate of death, stroke, and MI at three years were equivalent in patients with left main coronary disease treated...
Niraparib may lengthen progression-free survival for patients with recurrent ovarian cancer
1. Among patients with platinum-sensitive recurrent ovarian cancer, those who received the PARP inhibitor niraparib demonstrated significantly increased progression-free survival...
Molecular markers associated with bone marrow clearance in AML and MDS
1. TP53 mutant status significantly associated with bone marrow blast clearance after treatment with decitabine in patients with acute myelogenous...
Lower threshold for abdominal aortic aneurysm repair linked to reduced mortality
1. Repair of intact abdominal aortic aneurysms (AAA) was performed at significantly lower mean diameters in the United States than...
Palbociclib taken with letrozole increases progression-free survival in breast cancer patients
1. Patients with previously untreated estrogen receptor ER positive (ER+), human epidermal growth factor receptor 2 (HER2) negative breast cancer...
Ustekinumab linked with efficacy in treatment of Crohn’s disease: The UNITI-1 & 2, IM-UNITI trials
1. Ustekinumab achieved successful clinical induction in a greater proportion of patients with moderate to severe Crohn’s disease (CD) compared...
Pembrolizumab associated improved survival for NSCLC compared to platinum-based chemotherapy
1. Progression free survival and overall survival was significantly increased in patients who received pembrolizumab vs. patients who received platinum-based...
Nivolumab improves survival in head and neck squamous cell carcinoma: The CheckMate 141 trial
1. Nivolumab significantly increased median overall survival in patients with platinum refractory relapsed metastatic head and neck squamous cell carcinoma...
